drug

PF-03463275

as of 2026-07-01
Add to landscapeMonitor thisCompare thisAsk about this
at a glance
small molecule
Pre-approval / investigational in the US
Developed by Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
3 trials in the graph
Synthesized from structured facts only — each point cited above.

Mechanism & identity

Modality
small molecule

Indications

Trials

3
Translational Neuroscience Optimization of GlyT1 Inhibitor
NCT01911676Phase 2Completed
Pharmacokinetics, Safety and Tolerability Study of PF-03463275 in Healthy Male Japanese and Western Subjects
NCT01159626Phase 1Completed
A Study Of PF-03463275 As Add-On Therapy In Outpatients With Persistent Negative Symptoms Of Schizophrenia
NCT00977522Phase 2Terminated

KOLs & investigators

1
Deepak Cyril D'Souza, MDKOL score 7

Facts & assertions

0 sourced
No assertions recorded for this entity.
relationships
The graph out of here
developer
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
company
trial
Translational Neuroscience Optimization of GlyT1 Inhibitor
PHASE2
trial
Pharmacokinetics, Safety and Tolerability Study of PF-03463275 in Healthy Male Japanese and Western Subjects
PHASE1
trial
A Study Of PF-03463275 As Add-On Therapy In Outpatients With Persistent Negative Symptoms Of Schizophrenia
PHASE2
trial
indication
Schizophrenia
indication
Healthy
indication
Cognitive Impairments Associated With Schizophrenia
indication
Schizophrenia
indication
KOL
Deepak Cyril D'Souza, MD
KOL score 7
person